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Abstract 
A decade of discovery and development of new anti-malarial medicines has led to a renewed focus on malaria 
elimination and eradication. Changes in the way new anti-malarial drugs are discovered and developed have led to 
a dramatic increase in the number and diversity of new molecules presently in pre-clinical and early clinical develop-
ment. The twin challenges faced can be summarized by multi-drug resistant malaria from the Greater Mekong Sub-
region, and the need to provide simplified medicines. This review lists changes in anti-malarial target candidate and 
target product profiles over the last 4 years. As well as new medicines to treat disease and prevent transmission, there 
has been increased focus on the longer term goal of finding new medicines for chemoprotection, potentially with 
long-acting molecules, or parenteral formulations. Other gaps in the malaria armamentarium, such as drugs to treat 
severe malaria and endectocides (that kill mosquitoes which feed on people who have taken the drug), are defined 
here. Ultimately the elimination of malaria requires medicines that are safe and well-tolerated to be used in vulnerable 
populations: in pregnancy, especially the first trimester, and in those suffering from malnutrition or co-infection with 
other pathogens. These updates reflect the maturing of an understanding of the key challenges in producing the 
next generation of medicines to control, eliminate and ultimately eradicate malaria.
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Background
Nearly a decade has passed since the announcement by 
the World Health Organization (WHO) and the Bill & 
Melinda Gates Foundation of the long-term goal of eradi-
cation of malaria. Use of existing therapy over that period 
has helped drive a profound decrease in mortality and 
morbidity of 60 and 37% compared to that at the start of 
the Millennium [1]. Clear ‘road maps’ on the types of new 
medicines have now been discussed by the malaria com-
munity [2], and an ambitious goal of a further 90% reduc-
tion in morbidity and mortality set by the WHO [3]. Four 
years ago, a proposal was published for the types of mol-
ecules [target candidate profiles (TCP)] and medicines 
(target product profiles (TPP) needed [4], setting clear 
goals for new therapy. In this document, these concepts 
are updated, reflecting what has been learned about new 
medicines in the ‘pipeline’, what has been learned about 
the challenges of elimination and eradication, and the 
changing landscape of malaria. The ‘candidate’ in TCP 
refers to an individual molecule, and in the Medicines 
for Malaria Venture (MMV) portfolio, these compounds 
are in formal regulatory preclinical safety assessment or 
human volunteer studies. The ‘product’ in TPP refers to a 
final product, which may contain two or more active can-
didates, and, importantly, the appropriate formulation.
TPPs are strategic tools used to provide guidance dur-
ing drug discovery and development. While not manda-
tory, the US Food and Drug Administration (FDA) has 
published draft TPP guidelines [5], as these documents 
facilitate communication with regulators. As a minimum, 
TPPs provide platforms for a shared agreement about 
what constitutes success. In public healthcare, the pub-
lication and feedback for TPPs is a critical part of their 
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refinement. Since drug development takes over a decade 
to complete, TCPs and TPPs are living documents; they 
need to be updated to reflect changes in patient needs 
and the clinical landscape, new safety findings and tech-
nical progress (Table 1).
Malaria is an infectious disease, and resistant parasite 
strains will always emerge, requiring the continual gen-
eration of new molecules. The last 4  years has seen a 
new generation of compounds with novel mechanisms 
of action entering clinical development [6]. These have 
resulted from a combination of phenotypic screening 
and rational design, with four new compounds currently 
shown to be active in patients: OZ439 [7], KAE609 [8], 
KAF156 [9, 10], and DSM265 [11]. However, in the same 
4 years there have been increasing reports of multi-drug 
resistant malaria in the Greater Mekong Sub-region 
(GMS). The decreased artemisinin effectiveness is cor-
related with Kelch13 molecular markers [12]; in addi-
tion; there is resistance against partner drugs, such as 
mefloquine and piperaquine [13, 14]. It is not clear how 
long it will take for these resistant strains to have clinical 
impact in Africa [15] but this is a matter of great concern. 
The spread may be slowed by the successful deployment 
of triple combinations of artemisinin plus two part-
ner drugs, and this is being actively explored. It is clear 
that all new medicines need to be active against known 
resistant strains, and future-proofed against emerging 
resistance to the highest achievable degree. Currently, 
all new candidate molecules are tested against a wide 
variety of both clinically resistant strains and laboratory-
generated strains, and activity in these assays is a key 
requirement for moving forward. In the last few years 
several chemotypes have emerged against which it has 
not been possible to generate resistance in  vitro, using 
cultures of 109  parasites. Such resistance-proof ‘scaf-
folds’ will become an increasingly high priority. But given 
that the global parasite population emerging over a year 
approaches 1019 parasites, there is a need to be cautious 
about any extrapolation.
A focus on malaria eradication, rather than control 
requires prioritization of different types of medicines. 
The emphasis should be on breaking the cycle of disease 
transmission, rather than curing individual patients. Ide-
ally these should receive a single-dose regimen to simplify 
implementation. Most importantly such medicines need 
to be safe and sufficiently tolerated to be given to the wid-
est range of recipients, including infants and pregnant 
women. This is a continuum of benefit-risk, with one 
extreme being the potential to use treatments for sub-
jects with asymptomatic infections, or even those with no 
detectable infection [16]. The combined challenge of hav-
ing medicines that are (a) safe and well tolerated enough 
to be given to such a wide range of subjects; (b) effective 
enough to cure 95% with a single dose, and yet (c) suit-
able to be given to those with asymptomatic infections, is 
a formidable gold standard and there will inevitably have 
to be ‘trade-offs’. The early stages of malaria eradiation 
will require a differential deployment of currently regis-
tered medicines and development of new medicines for 
safe use in settings other than treatment of symptomatic 
malaria. There has been increased discussion about com-
bining three or more active molecules to combat resist-
ance. In addition, existing registered medicines, such as 
primaquine [17] and ivermectin, have been proposed as 
ways of breaking the transmission cycle [18].
A common platform for discussion of the ideal and 
minimally acceptable qualities of new medicines is 
important, given the 15-year time-frame from discov-
ery to launch. However, the ‘goal posts’ do move. Over 
the last 4 years, much has been learned about what the 
potential of new molecules entering clinical develop-
ment is, but also their limitations. There has been consid-
erable progress in mapping out the strategy for malaria 
elimination in individual countries, and an improved 
Table 1 Overview of newly defined TPPs and TCPs
Profile Intended use
TPP-1 Case management; treatment of acute uncomplicated malaria in children or adults. Uses a combination of two or more molecules with TCP-1 
activity, plus TCP-5 for reducing transmission and TCP-3 for relapse prevention, when such molecules become available
For severe malaria, a parenteral formulation of a single fast-acting TCP-1 would be appropriate
TPP-2 Chemoprotection: given to subjects migrating into areas of high endemicity, or during epidemics. Uses a combination of TCP-4 activity, 
potentially with TCP-1 support for emerging infections
TCP-1 Molecules that clear asexual blood-stage parasitemia
TCP-2 (profile retired, see body of text)
TCP-3 Molecules with activity against hypnozoites (mainly P. vivax)
TCP-4 Molecules with activity against hepatic schizonts
TCP-5 Molecules that block transmission (targeting parasite gametocytes)
TCP-6 Molecules that block transmission by targeting the insect vector (endectocides)
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understanding of the enormous challenges faced to eradi-
cate the disease. Based on these insights, these profiles 
have been refined and updated in discussions with the 
wider malaria community. These refinements help to 
identify progress, and highlight key gaps that remain to 
be overcome to achieve this ambitious goal.
Insights into new medicines for malaria indications
The ideal medicine proposed in 2011 was a single 
encounter radical cure and post-treatment prophylaxis 
(SERCaP [2]). This would contain at least two active 
molecules, preventing the emergence of resistance in 
blood schizonticides. (The post-treatment prophylaxis 
is assumed to be largely from the blood schizonticides 
preventing new infections, and so the term is simplified 
to SERC). Over the last 4  years there has been increas-
ing clarity on the role of different classes of medicines in 
elimination and eradication, both from WHO [3] and the 
UN Special Envoy for Malaria’s Aspiration to Action [19], 
which is summarized in Fig. 1.
The key role of new medicines for the medium term in 
this strategy is captured in this first TPP (TPP1; Table 2), 
for new medicines to treat malaria patients. In addition 
to the need to rapidly reduce parasitemia, the MalERA 
Agenda added the importance of preventing transmission, 
and of simplifying the therapeutic regimen from the cur-
rent three to six doses, to a treatment that could be given 
after a single encounter with a health worker. These con-
siderations remain a delicate balance to achieve (Fig. 5 in 
Ref. [4]). Over the last 4 years, a considerable body of data 
has become available on the safety of current medicines, 
in studies of tens of thousands of treatment events [20–
22]. Detecting and de-risking projects from the potential 
occurrence of rare, life-threatening adverse events (AEs) 
requires extremely large clinical studies, and malaria-
endemic countries do not provide strong self-reporting. 
This does underline the need for continued research using 
existing medicines; optimizing their uses depends on 
understanding the strengths and weaknesses of existing 
therapy. The critical issues are listed below.
What clinical efficacy is required for a single 
molecule?
In 2013 the language that was used to characterize new 
molecules was arguably outdated: it listed TCP-1, for 
molecules that cause a fast reduction of the parasite load, 
Fig. 1 The role of current and new medicines in driving the reduction of malaria to zero and maintaining elimination in countries ([3, 175] and 
‘malERA Refresh’, manuscript submitted). Given that even the most advanced new blood schizonticides will not be approved into policy until the 
2020s, much of the initial phase of reduction will be carried out using current medicines, continually optimized for deployment. Transmission block-
ing will be achieved by the use of insecticides and other vector control methods. As resistance develops there will be a need for new classes of 
medicines, ideally capable of shortening the treatment course and simplifying therapy (labelled here as SERC, but also including two- or even 3-day 
regimens). For countries in pre-elimination and elimination, new classes of chemoprotectants will be needed, and this need will arguably increase 
as the number of countries in pre-elimination increases
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similar to artemisinin, and TCP-2 for sustained anti-par-
asitic activity, as is seen with 4-aminoquinolines. In the 
last 4  years the characterization of the relative strength 
of blood schizonticides has improved, with concepts such 
as the total Parasite Reduction Ratio [23]. Clinically, an 
ideal schizonticide within a treatment should produce 
a sterilizing cure on its own. In monotherapy, all new 
compounds in clinical development show incomplete 
efficacy when given as a single dose, with an estimated 
PCR-adjusted per protocol adequate clinical and para-
sitological response (ACPR) at day 28) of 50–90% (the 
same range as marketed drugs). It is obvious that many 
compounds could achieve a complete cure by themselves, 
with repeated administration.
There is now a better understanding of the strength 
of the current molecules in the portfolio but because of 
their experimental nature, the early clinical studies of 
arterolane (OZ277 [24]) were limited to 6 h, while those 
of artefenomel (OZ439 [7]) and cipargamin (KAE609 
[25]) were limited to 36  h after the last administration 
of the test drug, precluding an analysis of recrudes-
cence later in time. But more recent studies in patients, 
such as those with a single dose of KAF156 [10], OZ439 
[26], DSM265 [27, 28] or three doses of ferroquine [29] 
have allowed a 28-day follow-up. The best molecules 
are now giving clinical efficacy of 70–90% when used as 
monotherapy.
Prior to testing in human subjects, the best surrogate 
is to estimate the total Parasite Reduction Ratio PRRtot 
[23] based on preclinical values. Estimations of minimum 
inhibitory and minimum parasiticidal concentrations 
(MIC and MPC) can be benchmarked against clinical 
observations [30]. Such translational pharmacokinetic/
pharmacodynamic (PK/PD) modelling and simulation 
provide a much better framework for ranking the anti-
malarial properties of molecules in the portfolio than the 
old bimodal fast-acting/short-duration versus medium-
acting/long-duration classification.
The single-exposure cure dilemma: efficacy 
versus safety in the wider population
Compounds that are used in combination to effect a sin-
gle-encounter radical cure must be extremely potent and 
extremely well tolerated. When providing the total dose 
into a single administration with prolonged duration of 
effective exposure, there is an increase in the maximum 
plasma concentration, which places additional safety 
constraints. Preclinical safety evaluation and early stud-
ies in volunteers and patients can rule out compounds 
which are likely to have a poor tolerability profile, espe-
cially issues around nausea and vomiting. However, 
given the limitations of AE reporting after approval in 
malaria-endemic countries, the full picture of rare, seri-
ous AEs is a critical public health need. Any safety signal 
detected in studies prior to registration must be further 
evaluated in the field through large phase IV studies. The 
work over the last 5  years on artemisinin combination 
therapy (ACT) underscores the scale of this problem. 
For amodiaquine–artesunate, a study with over 15,000 
malaria cases in Ivory Coast was required as part of the 
WHO-approved Risk Management Plan. Dihydroarte-
misinin (DHA)–piperaquine was linked to an increased 
QTc (corrected Q-T wave) interval but no further car-
diac sequelae; gathering data from over 16,000 patients 
[31], and 10,000 patients, including a nested study of 
1000 patients with thorough electrocardiogram (ECG) 
monitoring [32] has been required for this treatment to 
be accepted for WHO prequalification. Pyronaridine–
artesunate (Pyramax®) produced an acute, transient and 
asymptomatic elevation of liver enzyme levels in phase 
III patients, also seen in healthy Caucasian volunteers 
after re-dosing. A study of over 13,000 dosing events was 
needed before a European Medicines Agency (EMA) 
recommendation could be made to allow repeated dos-
ing without prior assessment of liver function tests [33]. 
Although malaria is treated as an acute infection, anti-
malarials need to be safe enough to treat multiple infec-
tions. The trend of requiring additional data increases 
both significantly the timelines for a new medicine to 
enter policy guidelines, and impacts costs.
Showing a medicine is sufficiently well tolerated in pop-
ulations with different risk–benefit profiles, such as those 
with asymptomatic infections [16], pregnant women [34], 
infants [35], and patients with other co-morbidities, such 
as human immunodeficiency virus (HIV) and tuberculo-
sis (TB) co-infection, or malnutrition, adds complexity. 
One medicine may not serve all these groups. There is a 
time challenge in pregnancy; because of ethical issues of 
recruiting pregnant women into studies, such safety data 
is at present collected passively. It has taken two decades 
post-Stringent Regulatory Agency (SRA) approval to col-
lect enough safety data to obtain a WHO recommen-
dation allowing the use of artemether–lumefantrine in 
first-trimester pregnancy [36–40].
The need to prioritize chemical scaffolds 
and combinations that are not prone to resistance 
generation
Although one can rank compounds based on their abil-
ity to generate resistant mutants in  vitro, the under-
standing of how this translates to clinical resistance and 
the transmission of resistance is too limited to be used 
for decision making. Recent studies with compounds 
from the open-access Malaria Box [41] have identified 
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several chemotypes against which resistance cannot 
be generated in the laboratory [42]. Attractive scaffolds 
from within this set will be prioritized for optimization 
and progress, and in parallel, target identification will be 
important.
Matching pharmacological duration of cover
ACT has very poorly matched pharmacological dura-
tions of cover, principally because of the PK mismatch, 
with concentrations of artesunate dropping below the 
clinically active concentrations within 12 h of each of the 
three daily doses, compared to the partner drugs main-
taining active concentrations for several weeks. All new 
pre-clinical candidates are now selected on the basis of 
being able to achieve active plasma concentrations for at 
least 4 and, in the best cases, 8  days. However, none of 
the new chemical classes, based on current knowledge, 
achieve the same coverage from a single dose as 3  days 
of treatment with 4-aminoquinolines or amino-alcohols 
[43]. Longer plasma exposure to provide greater post-
treatment prophylaxis will always be needed; total pro-
tection from re-infection for 28  days or even later after 
treatment would clearly be preferable [44].
Low variability of exposure and the absence 
of food effects are critically important
A combination that successfully treats at least 95% of 
patients must achieve adequate exposure in a minimum 
of 95% of patients who span a range of parasitemia bur-
den and sensitivity. Therefore, reduced variability of 
exposure is important. Candidate molecules whose expo-
sure is independent of food effects in humans are ideal. 
Food intake cannot always be controlled in the field, in 
particular the first day of treatment during the most acute 
phase of the disease, and the fat composition of food 
is highly variable, especially in low-income countries. 
These factors are even more important when consider-
ing a single-encounter cure rather than a 3-day regimen. 
Unfortunately, the absence of a food effect in preclinical 
development does not always predict the human situa-
tion and so this has to be verified clinically. Modelling of 
the variability of exposure in humans is a critical activity.
More potent molecules are needed
Current clinical candidates have human dose predic-
tions of between 30 and 1000 mg for a single, adult dose. 
It would be good to increase the stringency of selec-
tion here; compounds with doses <25 mg in infants and 
100  mg in adults will be critical to reduce pill size, for-
mulation volume, increase tolerability, and reduce the 
occurrence of vomiting. Compounds that require exten-
sive formulation development are also problematic, espe-
cially since formulation adds considerably to the mass of 
the medication. The major cost driver is the quantity of 
drug in the treatment rather than cost per kilogram per 
se, thus more potent molecules would generally also lead 
to cheaper therapy.
Combinations with two new chemical classes 
would be preferred
Four years ago, with no new molecules in later-stage 
development, the priority was to deliver any new medi-
cine. This has led to phase IIb study proposals where 
new drugs were partnered with the best of the existing 
anti-malarials, typically piperaquine. This trend has now 
been tempered by a better understanding and apprecia-
tion of partner drug resistance. The current combinations 
in phase IIb (OZ439, KAF156) are partnered with mole-
cules from known scaffolds, but selected to minimize the 
risk of cross-resistance with marketed and clinical-stage 
anti-malarials. For example, ferroquine is a new 4-ami-
noquinoline without cross-resistance to piperaquine [45]. 
Clinical resistance to lumefantrine is a matter of active 
current discussion, but appears not yet to be widely 
reported, and in  vitro resistant mutants have not been 
identified [46]. In the coming 4 years the next-generation 
combinations entering phase IIb combination studies 
should contain two completely new chemotypes. Combi-
nations of two or more new compounds are considered 
more complicated from a regulatory viewpoint. Putting 
together two new compounds is inherently more risky 
because the potential issues of the newer compounds are 
likely not yet evident. It may be that malaria mirrors drug 
development for other infectious diseases, with registra-
tion as a single agent (for use in combination with cur-
rent therapy), but deployment as new combinations. This 
is a critical debate.
Compounds ideally need to target more than one 
Plasmodium life-cycle stage
Although most of the current portfolio was originally 
identified from screening against asexual blood schizonts, 
many compounds have been shown to have activity in 
cellular assays for transmission-blocking (preventing the 
production of stage V gametocytes) as well as for chemo-
protection (inhibition of developing hepatic schizonts). 
Any new combination must either have transmission-
blocking efficacy itself, or be compatible with low-dose 
(0.25  mg/kg) primaquine, which is the WHO-approved 
regimen for transmission blockade. Considering the 
relapse of dormant Plasmodium vivax or Plasmodium 
ovale, no new scaffolds beyond 8-aminoquinolines have 
been identified with anti-hypnozoite activity and poten-
tial for development. In phase II studies, the 8-aminoqui-
noline tafenoquine has demonstrated high activity as a 
single dose [47]. A new candidate needs to have a similar 
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efficacy to tafenoquine, but without the potential risk 
of hemolysis in patients with low glucose-6-phosphate 
dehydrogenase (G6PD) activity. New candidates are rou-
tinely tested in new animal models to monitor the risk of 
such hemolysis [48].
The fact that the new generation of compounds, when 
administered alone, cannot fully clear all asexual and sex-
ual stage parasitemia with a single dose is not surprising, 
since none of the previous generation of therapy could. 
Going forwards, combinations in clinical trials may 
require multiple exposures, or single-exposure combina-
tions of three or more entities to be successful in the vast 
majority of patients. Treatment with three or four drugs 
is becoming standard in other diseases such as TB [49], 
HIV/AIDS [50] and neonatal sepsis [51].
There has been increased discussion about the need to 
treat asymptomatic carriers, particularly in the context 
of disease elimination and eradication, to reduce the 
parasite reservoir [16]. Asymptomatic malaria causes 
significant co-morbidity through anemia [52]; how-
ever, it remains to be established if this risk on its own 
is sufficiently severe to justify the administration of a 
full treatment course. Moreover, the recent observation 
that the malaria parasite burden correlates positively 
with survival from Ebola infection will complicate this 
further [53]. Median parasite burdens may be lower in 
asymptomatic populations [54], but their range overlaps 
with the range found in uncomplicated symptomatic 
malaria patients (Kamija Phiri et  al., submitted; the 
median baseline was 1240  parasites/ml and the range 
was 80–55,400/ml in asymptomatic subjects). Similar 
potencies are likely to be required to provide asexual-
stage clearance in asymptomatics or symptomatics. 
However, in the context of elimination and eradication, 
the purpose of treating asymptomatics is principally 
important to decrease the parasite reservoir and reduce 
transmission. Indeed, elimination and eradication of 
a Plasmodium species will only be feasible via a com-
prehensive malaria treatment programme administer-
ing combinations to all, such as mass screen-and-treat 
(MST), seasonal malaria chemoprevention (SMC), or 
even mass drug administration (MDA). Treating asymp-
tomatic or parasite-free healthy subjects will require 
higher degrees of safety, such as typically required for 
vaccines.
A key goal of treating asymptomatics is to not only 
eliminate the asexual parasites but also the gametocyte 
populations. With current compounds, effects on game-
tocytes are often weaker than on the asexual stages, 
and there is a clear need for compounds with specific 
transmission-blocking capabilities measurable in human 
transmission models. Understanding the activities of 
the current ACTs in asymptomatic malaria will be a key 
part of refining whether a new TPP is required for this 
indication.
Insights into new medicines for reducing the 
incidence of malaria cases
The significant reduction in the incidence of overall 
malaria infection over the last 15 years has been achieved 
by protecting the at-risk populations, particularly with 
insecticide-treated bed nets [55] and spraying with 
insecticides and larvicides [56]. Vaccination represents 
another potential strategy, and although recent results 
with the RTS,S vaccine are encouraging, they are cur-
rently far from the level required to drive eradication 
alone [57, 58]. Other approaches such as radiation-atten-
uated sporozoite vaccines are under investigation [59]. 
Antimalarials offer an additional approach to reducing 
the incidence of malaria. The previous TPP proposal [4] 
had described single exposure chemoprotection (SEC) as 
the second TPP-2). The terminology is important here. 
This review uses chemoprotection to describe medicines 
used to protect subjects entering an area of high ende-
micity. In addition, in the final stages of malaria elimina-
tion and eradication, these could also protect populations 
at risk from emergent epidemics. Chemoprevention, in 
the sense of SMC, is used today to describe medicines 
with demonstrated efficacy for treatment at full treat-
ment doses (because some of the subjects treated will be 
asymptomatic carriers), given regularly to large popula-
tions who live in areas of high endemicity.
These two interventions play different roles at different 
times in eradication as illustrated in Fig.  2. Chemopro-
tection is a critical success factor later on for protecting 
migrant populations, and protecting static populations 
against new epidemics. Chemoprevention is most effec-
tive in high-transmission settings, and so is a critical suc-
cess factor in the early stage of elimination. This review 
includes here a TPP-2 for chemoprotection, in addition 
to the TPP-1 for treatment (Table 3).
Chemoprotection
A SEC medicine would optimally be a combination of 
two compounds, with minimal acceptable profile of 
causal liver stage activity, plus potential benefit from 
activity against asexual blood stages, which need not be 
fast-onset. The definition of this TPP, TPP-2, was con-
ceptually built around atovaquone-proguanil (causal 
liver stage activity, and a profile tolerance for slow onset 
of action against asexual blood stages). It is an open dis-
cussion whether this needs to be a combination of two 
molecules, given that they face a relatively low burden 
of parasites. However, as soon as asexual blood-stage 
activity is included, there is an increased risk of selec-
tion of mutants, and pharmacodynamically matched 
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combinations would be ideal. Frequency of administra-
tion is a critical question here; monthly, or even less-fre-
quent dosing would be ideal, but weekly is still an option 
although it would have considerable consequences for 
implementation.
All the molecules in the malaria portfolio are now rou-
tinely tested for causal liver-stage activity, required for 
TCP-4, and many show good activity in vitro. However, 
the pharmacokinetics of these new molecules would 
only support a once weekly rather than once per month 
administration. Resistance generation for compounds 
with pure hepatic schizont activity is less of a concern, 
since the parasite burden is so much lower in the hepatic 
stages rather than the blood stages. However, new drugs 
should be active against pre-existing resistance muta-
tions (including those to atovaquone). The pathway for 
regulatory approval still needs to be clearly defined and 
this will be a challenge over the next 5 years. Safety is a 
major concern as the drug would be administered to a 
broad population. The presence of long-duration blood 
schizonticide activity (TCP-1; Table  4) in one or more 
of the active ingredients in such a medicine may be an 
additional advantage for chemoprotection, since many 
subjects may have asymptomatic infections, and fluctu-
ating parasitemia which may at times only be detectable 
by PCR. However, it does increase the risk of resistance 
generation.
The insights into the development of new medicines for 
chemoprotection over the last 4 years in this area can be 
summarized as follows.
1. Confirmation of the activity in humans for activity 
against hepatic schizonts or newly emerging asexual 
erythrocytes can now be tested in controlled human 
malaria infection (CHMI) volunteer studies using 
either injected cryopreserved sporozoites [60, 61] or 
infectious mosquitoes [62]. Currently these models 
involve infection of non-immune volunteers who live 
Fig. 2 Inter-relationships between the two high-level target product profiles (center) with the individual target candidate profiles (left) for mol-
ecules that are part of the product. The uses for each product are summarized on the right
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in non-endemic regions, and so it will be important 
to extend this work to include studies of the impact 
on the immune response, and in an expanded genetic 
background.
2. Historically, new medicines for chemoprotection 
have been destined for use by Western travellers. In 
an elimination and eradication campaign the priority 
population will be primarily travellers within Africa, 
travelling from areas of high endemicity to areas of 
low endemicity. In countries newly free from malaria, 
chemoprotection could also be used to protect the 
general population should they be at risk from epi-
demics. Molecules with chemoprotection activity 
should be tested on subjects with the correct ethnic-
ity, and opportunities for this occur in people living 
in previously endemic zones, but now moving to 
endemic zones: for example, migrating from south to 
north Zambia, or west to east Gambia.
3. The most advanced malaria vaccine, Mosquirix (RTS, 
S-AS202) has been given a ‘positive scientific opin-
ion’ by the EMA, but has sub-optimal and short-lived 
efficacy. The current course of vaccination involves 
three or four 0.5  ml intramuscular injections with 
a 25-gauge needle, at a cost of around $5 per injec-
tion. This has raised the possibility that small mol-
ecules could play a key role in long-term protection. 
An injectable sustained-release formulation would 
be acceptable if efficacy could be delivered by three 
or four injections per year. In HIV, where developing 
an effective vaccine has also been a major challenge, 
such an approach (called pre-exposure prophylaxis, 
or PrEP) is being studied [63], leading to the develop-
ment of long-acting, nano-milled, injectable formula-
tions aiming at 3  months or longer protection [64]. 
A TCP for an injectable chemoprotective agent for 
malaria can be developed (Table 5).
Chemoprevention
Chemoprevention is defined primarily in the context 
of current thinking on SMC [65] and related strategies. 
SMC is currently defined as the intermittent admin-
istration of full treatment courses of an anti-malarial 
medicine during the malaria season, to prevent malarial 
illness. The objective is to maintain preventative anti-
malarial drug concentrations in the blood throughout 
the period of greatest malarial risk. The high efficacy of 
SMC campaigns with sulfadoxine-pyrimethamine plus 
amodiaquine [66–70] highlights a potential wider role for 
this approach in the future, possibly in combination with 
vaccination. Concerns over sulfadoxine-pyrimethamine 
resistance in Africa south of the Equator [71] has led to 
trials of monthly 3-day courses of ACT in chemopreven-
tion [70], contrasting with the WHO recommendation to 
use different medicines for chemoprevention and treat-
ment [72]. This review does not propose a TPP for chem-
oprevention. The likely time-lines for the development of 
such a medicine based on new chemical entities would 
take too long for it to be useful in the elimination agenda. 
The reality is that chemoprevention in high-transmission 
zones will continue to use the drugs that are currently 
available.
The regulatory pathways for new medicines in chemo-
protection and chemoprevention still need to be clarified: 
SRAs may require a clearer basis for the dose selection 
than that used previously for atovaquone-proguanil and 
mefloquine. An updated draft strategy (Macintyre et al., 
unpublished) would establish an understanding of drug 
exposure needed for chemoprotection and chemopre-
vention in addition to that required for curative treat-
ment, as these exposures may differ.
Severe malaria
In severe malaria, patients are often unconscious or 
otherwise too sick to take oral medication. At this 
stage of disease, the sequestration of large numbers 
of parasites in the microvasculature of the brain leads 
to brain swelling [73], and in some cases affecting the 
lungs and other vital organs, which may rapidly lead 
to death, whereas in young children the major com-
plications may result from severe anemia. Any new 
medicine would therefore have to free up the micro-
vasculature, either by disengaging or killing the para-
sites; the drug’s speed of onset of activity is therefore 
of paramount concern. The AQUAMAT and SEAQ-
UAMAT studies that compared intravenous artesunate 
and intravenous quinine [74, 75] and other studies that 
compared intravenous or intramuscular artesunate 
[76, 77] showed that injected artesunate reduces the 
overall severe malaria patient mortality by between a 
third and a quarter. From a safety viewpoint, quinine 
use has been associated with injection-site patholo-
gies, cinchonism [78, 79] and also risks of hypoglyce-
mia. Artesunate, as used in severe malaria, has been 
linked with late-onset hemolysis [80–82], with the 
associated increased clinical risk, and it would be 
important to establish early on if this is a general issue 
for all fast-acting compounds. Any ideal next-genera-
tion molecule would clearly not have these disadvan-
tages. Artesunate suppositories have been proposed 
for pre-referral of severe malaria [83], specifically for 
children under 6 years old who are more than 6 h away 
from a hospital, but this formulation also may offer 
an approach to severe malaria when intramuscular 
injection is not possible. Simpler, pre-filled injection 
devices would be useful, but have to contend with the 
instability of artesunate in aqueous media.
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Artesunate resistance has been a concern in the GMS 
for almost a decade, and parasite reduction half-lives of 
12–15  h have been reported [84], representing a four- 
to six-fold reduction in speed of kill compared with the 
treatment of African patients. Ultimately a new fast-
acting compound may be needed to treat severe malaria. 
The development route for a new product targeting 
severe malaria would not be easy [85], since adult cases 
of severe malaria are rare, and proceeding directly to 
pediatric patients would be ethically difficult. Any piv-
otal trial would need to be large; for example, artesunate 
required data from over 6000 severe malaria cases [74, 
75]. If artesunate fails for severe malaria, any new drug 
would have to perform better than injectable quinine, 
which would revert to being the gold standard. One start-
ing point would be the further development of the rapid-
onset TCP-1 molecules (as such TPP for severe malaria is 
a product using a molecule from a sub-set of the TCP-1 
portfolio). Since many of these are relatively hydropho-
bic, this would require the development of a parenteral 
formulation as a first step. Amongst the current portfo-
lio KAE609 clears parasites more rapidly than artesunate 
and could have value in severe malaria if a parenteral 
formulation were available [8]. Other PfATP4 inhibitors 
are in development, with SJ733 (+−SJ00557733; [86, 87]) 
recently starting phase I studies. A concern with target-
ing PfATP4 is that mutations in this gene confer resist-
ance against aminopyrazoles, dihydroisoquinolones and 
spiroindolones [42, 88, 89]. The developmental pathway 
could be to demonstrate safety and tolerability of a par-
enteral formulation whilst assessing activity in adults 
with moderately severe malaria (hyperparasitemic cases; 
[85]).
Facilitating rapid de-sequestration has also been sug-
gested as a therapeutic mode of action for severe malaria, 
with recent clinical testing of the anti-rosetting com-
pound sevuparin [90]. One could hypothesize that a 
compound that blocks sequestration keeps parasites 
in the vasculature and thus increases the ability of both 
the spleen and the immune system to clear these. From 
a safety perspective, the concern would be to show that 
rapid de-sequestration did not lead to splenic overload 
from released, but damaged erythrocytes. Currently no 
candidate profile has been developed.
Approaches to reduce neurological sequelae or mod-
ulating the innate immune response have not advanced 
much. The conventional path forward would be to test 
medicines with a known pediatric safety record as 
adjunct therapy along with parenteral artesunate. How-
ever, the success rate to date has been extremely poor 
[91]. Perhaps the availability of standard neurological 
assessment technologies, such as magnetic resonance 
imaging (MRI) in malaria-endemic regions [92] will 
provide new insights. The safety/efficacy equation is 
somewhat different for severe malaria, due to the high 
risk of death; a rapid onset of action is the most criti-
cal factor. It is to be noted that many preclinical animal 
models for severe malaria have been reported and used 
for compound testing but, unfortunately, the validation 
of these models is poor, simply because compounds 
have been unable to be taken forward for confirma-
tion in humans. Critically, it is only data in humans and 
ultimately children that could provide sufficient valida-
tion to justify further clinical work. Recently genetic 
and experimental data were obtained that suggest that 
elevated levels of angiotensin II may protect from mor-
tality due to cerebral malaria [93]. If true, this may pro-
vide opportunities for adjunct treatments for severe 
malaria.
Selecting medicines for use in pregnancy and small 
children
Accelerating the safety assessment of new medicines in 
pregnancy is extremely challenging. The history of the 
assessment of artemisinin in first-trimester pregnancy 
shows how difficult the path is. Although preclinical 
safety signals were seen in many experimental species, 
no overt increase in birth defects or early abortions have 
been seen with artemisinin use in humans. To establish 
that there was not a twofold increase in the risk of such 
an event, an analysis of some 800 reported inadvertent 
ACT exposures in first-trimester pregnancy was needed 
[39, 94, 95]. For any new medicine, it would usually be at 
least a decade after launch before such data were avail-
able, underlying the need for more investment in the 
post-registration safety monitoring in disease-endemic 
countries. In the meantime, the best approach is at least 
to triage new compounds for any potential risk factor in 
early pregnancy by bringing forward the standard regu-
latory examination of early embryo-fetal development 
(EFD) toxicity. This is conventionally done in parallel 
with phase II, but MMV is now routinely performing 
this ahead or in parallel with phase I, and plans to make 
it part of its standard preclinical safety assessment. Fur-
thermore, within discovery, MMV is exploring state-
of-the-art in vitro and in vitro models for assessing and 
predicting reprotoxicity and teratogenicity, including 
(non-human) whole embryo cultures, embryonic stem 
cells and zebra fish embryos. Unfortunately, none of 
these methods has yet reached the level of confidence in 
predictive value that has been achieved for in vitro geno-
toxicity assays such as the Ames assay, and thus the earli-
est regulatory-relevant assays remain the rat and rabbit 
EFD studies. An alternative approach to small molecules 
would be the use of monoclonal antibodies in this patient 
population, since the off-target liabilities of monoclonal 
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antibodies are accepted to be lower than for small 
molecules.
Symptomatic malaria infections are particularly com-
mon in small children and infants in disease-endemic 
countries. The main reason is the lack of a protective 
immune response. During clinical development it is 
therefore important to verify early on that medicines are 
effective in populations from countries with low malaria 
endemicity, to ensure that the medicine can be fully 
active without immune support. For pediatric medicines, 
it is important to fully understand compound exposures 
and the relationship between exposure and efficacy (PK/
PD) in small children and then to adapt dosing accord-
ingly. Typically the clinical studies have included chil-
dren as young as 6  months, or 5  kg in weight. Between 
6  months and 2  years old, the development of the liver 
and the re-distribution of fat in the infant often translates 
into substantially different exposures for similar dos-
ing [96]; the International Conference of Harmonization 
(ICH; [97]) has recommended to divide childhood into 
five phases with respect to clinical drug use, reflecting 
this complexity. But only adults can be enrolled in clini-
cal trials prior to phase II studies. One of the goals of the 
next few years is to better model the factors that control 
drug uptake, distribution and metabolism in small chil-
dren. The other concern is safety, and it should be possi-
ble to accelerate preclinical juvenile toxicology studies to 
get an early read-out as to whether new compounds have 
any specific safety concerns.
Linking the TPPs to individual molecules and TCPs
Both high-level TPPs require a combination of biological 
activities, and each of these can be defined by a TCP. The 
nuance is that a single molecule can achieve more than 
one TCP, for example having asexual blood-stage activity 
(TCP-1) plus transmission blocking (TCP-5). In total, any 
new combination medicines must have sufficient of these 
activities to achieve the TPP. This framework helps to 
define gaps in the current TPPs that are currently under 
discussion. For example, in the vaccine community, vac-
cines purely targeting the transmission of Plasmodium 
falciparum are under development, targeting Pfs25 [98–
100], Pfs230, Pfs48/45 or (Anopheles) AgAPN1 [101]. 
Currently no such medicines exist, since all the molecules 
in development that have transmission-blocking activity 
on the parasite also impact the blood stages. However, 
with the increased attention to molecules blocking trans-
mission through endectocide activity, there is discussion 
on the inclusion of a TPP for this activity, which could 
be a mixture of TCP-6 and pure TCP-5 molecules. Severe 
malaria products could also be included in this chart, as 
the sub-set of fast-acting TCP-1 molecules that are suit-
able for parenteral formulation.
Insights into the evolution of TCPs
Proposed changes to the nomenclature
Although this review’s description of TCPs helped 
develop a common language in the development of leads 
and preclinical candidates, there are many areas where it 
can be improved. As discussed above, for the blood schi-
zonticides, the separation of compounds with rapid effect 
or long duration of action (TCP-1 vs TCP-2), is a histori-
cal artefact. Compounds in development have all been 
selected for long duration (a predicted pharmacologically 
active plasma exposure in humans of more than a week), 
as well as either fast or very slow parasite reduction. A 
more useful way of comparing compounds is by combin-
ing the speed of kill and PK into a total Parasite Reduc-
tion Ratio (PRRtot; [23]), giving a numerical index to the 
overall ‘strength’ of the compounds. These two profiles 
have now been merged into a single, new TCP-1 focused 
on clearance of asexual blood-stage parasites, and the 
TCP-2 nomenclature has been retired (Table  6). Medi-
cines for severe malaria would be a sub-set of this TCP-1, 
with rapid onset of action and where a suitable parenteral 
formulation can be developed. (With the focus in the last 
4 years on registering artesunate for injections and sup-
positories, this has not been a priority, but in the future 
new parenteral formulations of fast-acting compounds 
will become more important.)
The description of TCP-3a and 3b, originally based 
on activities of primaquine against the extra-erythro-
cytic forms has been confusing. TCP-3 has now been 
re-defined as the activity against hypnozoites directly 
(or indirectly through pathways such as apoptosis or 
autophagy) [102], or forcibly re-activating these so that, 
once metabolically active, they can be killed by a partner 
drug, analogous to the dormant HIV ‘shock and kill’ strat-
egy [103, 104]. TCP-4 describes the attributes for activity 
against hepatic schizonts, as part of chemoprotection.
TCP-5 replaces the previous TCP-3b and describes 
molecules with transmission-blocking activity. This is 
one area where understanding has developed consider-
ably over the last 4 years. The clinical reference for this 
is low-dose primaquine [105, 106]. Ideally, a candidate 
would have activity against all five differentiated forms 
of gametocytes (stages I–V), plus inhibition of oocyst 
or sporozoite formation in the mosquito vector. For P. 
vivax, gametocyte differentiation is coincident with asex-
ual blood-stage proliferation and since all compounds 
that affect asexual vivax malaria appear to also kill vivax 
gametocytes, no special focus is required in this area 
[107]. Direct screening methods to find a transmission-
only molecule have now been described [108], with the 
potential advantage of finding molecules that are less sus-
ceptible to resistance, however their clinical development 
path is more difficult [109]. The role of endectocides 
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in transmission blocking has received much attention 
[18, 110], and the initial framework for a corresponding 
TCP-6 has been introduced. There are ongoing discus-
sions at the WHO, which will further refine this over the 
next 12 months.
Establishing new, individual TCPs for anti-relapse 
(TCP-3; Table  7) and transmission blocking (TCP-5; 
Table  7) also re-emphasizes the critical importance of 
these two TCPs for elimination and eradication of Plas-
modium spp, and the progress made since the last pub-
lication in defining appropriate drug discovery cascades 
[111]. The profiles are described in more detail below. 
Each describes a set of attributes for a single compound, 
for which there should be increasing confidence as the 
compound moves from lead (active in animal models 
[112]) through selection as a candidate drug, preclinical 
evaluation and phase I(a) studies to a demonstration of 
activity in humans in either CHMI models [26, 27, 30, 
43, 113, 114], classically described as phase Ib, or early 
exploratory monotherapy patient studies (described 
as clinical exploratory, or phase IIa). Each TCP details 
a ‘minimum essential’ and an ‘ideal’ profile. The ‘ideal’ 
criterion builds on what is described in the ‘minimum 
essential’; criteria are not repeated unless there is a 
change.
TCP-1: ‘asexual parasite clearance’, reducing the 
parasite burden
The management of malaria cases requires the complete 
elimination of asexual parasites. The current combination 
treatments can achieve a cure rate (ACPR) assessed 28 or 
42 days after treatment, in more than 95% of the (per pro-
tocol) population. How much drug is required, and how 
effective it needs to be to reduce parasitemia to below 
detectable levels in 19 out of 20 subjects will include fac-
tors such as the patient’s initial parasite burden, variabil-
ity of drug exposure and immune status. However, for 
comparing molecules, the two key factors are the rate 
of parasite reduction (PRR) and the time over which an 
efficacious plasma concentration can be achieved [115]. 
These can be integrated to give a  PRRtot [23], as a meas-
ure of the power of an individual molecule. The rank 
order of PRRs can be estimated in vitro [116, 117], or in 
SCID  (severe combined immunodeficient) NOD-SCID 
IL2Rδ−/− mice [118]. Molecules can be initially ranked 
as very fast (such as PfATP4 inhibitors), fast (artesunate 
and other endoperoxides) and medium (as fast as meflo-
quine). These initial estimates can then be confirmed in 
CHMI models [26, 27, 30, 113, 114, 119] and other pilot 
clinical studies [7]. The estimates of the MIC and MPC 
from the SCID mouse model appear to correlate well 
with the values seen in humans [30]. The human treat-
ment dose can be simulated for single or multiple doses 
by combining these data with the predicted human PK 
using standard methods that rely on preclinical in  vivo 
PK and in  vitro metabolism data. Studies with KAE609 
in Plasmodium berghei-infected mice confirmed that 
efficacy correlated best with the area under the curve 
(AUC), i.e., an integration of exposure over time, or time 
with exposure above threshold level, rather than purely to 
Cmax. Further studies using the SCID mouse model, using 
dose fractionation, will be important going forwards to 
determine if this is general the case. One notable excep-
tion already identified is artesunate, where the plasma 
residence time is much shorter than the duration of the 
parasite lifecycle, and the efficacy is more simply linked 
to its Cmax [120, 121].
An ideal TCP-1 compound, based on this review’s new 
definition, should be able to reduce parasitemia (PRRtot) 
1012-fold by itself, based on curing adult patients with as 
high as 200,000 parasites/ml. This would hold for patients 
at the lowest fifth percentile of the predicted human 
plasma exposure variability. Setting preclinical criteria to 
discontinue a compound is difficult because of the lack of 
precision in PRRtot estimates. These are highly dependent 
on the accuracy of terminal half-life estimates, which are 
exponentially related; a twofold longer half-life will cause 
a squared increase in the fold parasite reduction. This 
review pragmatically set the rule of thumb in discovery 
of 106-fold reduction from a single dose. Also important 
is the shape of the concentration–time curve in humans. 
A low peak-to-trough ratio is desirable in order to mini-
mize problems in safety and tolerability and maximize 
the duration of efficacy (i.e., the time above MPC) at the 
same time as limiting Cmax-related safety issues.
It remains under discussion as to whether there is a 
minimum rate-of-reduction criterion in parasitemia. 
The previous publication [4] focused purely on the rate 
of reduction, using 4-aminoquinolines as the bench-
mark. Experimental evidence shows that piperaquine 
has a 1og10 PRR over 48  h of around 3.4, or a parasite 
reduction half-life of 4.2  h [122]. Similar rates of para-
site reduction have been reported for chloroquine [123] 
placing some 4-aminoquinolines as relatively fast killers 
clinically, with similar kinetics of parasite reduction as 
artesunate. Thus, the earlier criterion may have been too 
stringent; mefloquine and ferroquine for example, are an 
order of magnitude slower [30, 43]. The onset of action 
(lag phase) on parasitemia appears less important pro-
vided that, as a minimum, growth is immediately halted 
and then followed by rapid parasite clearance. Pyrimeth-
amine, for example, is clinically highly effective on sen-
sitive parasites despite having a delayed onset of action 
of approximately 24  h, because it subsequently clears 
parasites quickly and has a long human plasma half-life 
of 96 h. However, compounds with a long fever clearance 
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time may present compliance challenges and safety con-
cerns, especially in children.
Finally, TCP-1 molecules should ideally show good 
activity against the blood stages of all five Plasmodium 
species that infect humans. The difficulty of comparing 
data across species in in vitro assays comes from the fact 
that only P. falciparum is widely cultured, while most of 
the other Plasmodium species are tested ex vivo. Whilst 
the testing of preclinical candidates on field isolates (P. 
falciparum and P. vivax) or laboratory-adapted strains 
(P. falciparum and Plasmodium knowlesi) is becoming 
increasingly feasible, access to P. ovale and Plasmodium 
malariae parasites is extremely limited and, thus, activity 
against these two species is usually assumed rather than 
measured. Only in the case of pyronaridine-artesunate 
has activity against other species (P. vivax) been sup-
ported by clinical data in the stringent regulatory filing 
[21, 124]. The consensus is therefore that ‘ideal’ new mol-
ecules should have clinical activity demonstrated against 
P. falciparum, and comparable efficacy against other spe-
cies in vitro, where obtainable.
As noted earlier, there is no specific TCP for severe 
malaria, since such compounds are a discrete sub-set of 
TCP-1 provided they produce appropriate immediate 
and rapid parasite clearance, are well tolerated and can be 
developed as an injectable. Compounds with a slow onset 
of action against blood stages, such as the macrolide anti-
biotics, have potential to play a role in chemoprotection, 
as explained in TPP-2 above, but only with safety, potency 
and PK to support dosing once per week or less often.
TCP-3: targeting Plasmodium hypnozoites
The definition of a radical cure is the removal of all forms 
of the parasite from an infected individual, not just the 
asexual stages that cause symptoms. Whilst this defini-
tion covers all non-asexual blood stages, the focus of 
TCP-3 is on the form that is the hardest to kill: the dor-
mant liver stages that follow new P. vivax and P. ovale 
infections. To be effective in vivax and ovale endemic 
regions, any new anti-malarial drug combination requires 
a molecule which can either kill the dormant hypnozo-
ites directly, or through host-mediated pathways such 
as apoptosis or autophagy, or re-activate them, allowing 
them to be killed by other molecules in the combination. 
The gold standard for this profile remains primaquine, 
which is effective against P. vivax and, presumably, P. 
ovale hypnozoites. Primaquine has three weaknesses: 
compliance is poor, given the 14-day therapy course in 
asymptomatic individuals; gastro-intestinal tolerabil-
ity; and the increased risk of hemolysis in patients with 
reduced G6PD activity.
Progress towards finding new TCP-3 molecules has 
been extremely challenging and hampered by the lack 
of cellular assays that directly measure hypnozoite inhi-
bition. Until recently the gold standard was the double 
surrogate of in vitro infection by Plasmodium cynomolgi 
sporozoites of rhesus hepatocytes [125]. This links 
directly to the current gold standard in  vivo primate 
model [126], but with the disadvantage of the species dif-
ference of both parasite and host cell.
Hypnozoite assays using primary human hepatocytes 
in co-cultures or spatial confinement [16, 127], or human 
cell lines [128, 129] have been established recently, and 
are now suitable for testing in either eight-, 96- or 384-
well formats. However, supply of sporozoites for infec-
tion remains a major limiting factor for going forwards 
[130, 131]. Importantly, statistically useful measures of 
inhibition are now being obtained in 96-well and 384-
well formats. These allow functional activity of hypno-
zoites and schizonts to be monitored and even in  vitro 
relapses to be observed [132]. The exact protocol for 
compound incubation is important, given the time 
required to develop particular parasite forms. Significant 
activity in such assays is hard to define, since primaquine 
is relatively inactive in vitro, depending on the metabolic 
activity of the cells [102, 133]. Pragmatically, a threshold 
for in  vitro activity of EC50  <  100  nM against hypnozo-
ites has been set, although less potent compounds with 
acceptable safety profile at high plasma exposure would 
also fit the bill. New in vivo models that use human liver-
chimeric mice have demonstrated infections with P. vivax 
sporozoites, formation of hypnozoites and liver schiz-
onts, providing potential new preclinical models [134], 
although these are still a long way from routine use.
New clinical models [135] and clinical trial designs 
[136] mean that the anti-relapse potential of new clini-
cal agents can now be measured reliably in humans, 
since, strictly speaking, the predictive power of the pri-
mate model has only been demonstrated for 8-amino-
quinolines. The success of the tafenoquine phase II trials 
[137] underscores that it is possible to obtain definitive 
clinical data on relapse at 6 months, establishing a clini-
cal proof-of-concept benchmark for this compound class. 
Tafenoquine does have the liability of hemolysis in sub-
jects with reduced G6PD activity, and so the ideal next 
generation compound would be one that did not require 
G6PD monitoring.
TCP-4: targeting hepatic schizonts
The terminology here has often been confusing, and it is 
important to repeat the definitions made earlier. Chem-
oprotection, as part of the SEC, is the use of medicines 
to protect subjects entering high-transmission zones 
from an area without malaria transmission, or to pro-
tect those in malaria-free areas at risk of epidemics in 
the final stages of malaria eradication. (This is distinct 
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from chemoprevention, as in SMC, which is the use of 
full courses of blood schizonticides to prevent clinical 
malaria in populations that reside in endemic areas). This 
review uses the term TCP-4 activity to describe hepatic 
schizonticide activity. Historically, medicines that pro-
vide chemoprotection had erythrocytic schizonticide 
activities (TCP-1) as illustrated by atovaquone-proguanil 
(with TCP-1 and TCP-4 activity), or even compounds 
such as mefloquine, that is exclusively a TCP-1 com-
pound. However, in designing new chemoprotectants, it 
is clear that the research community needs to proactively 
search for molecules with hepatic schizont activity.
No compound with pure TCP-4 activity currently 
exists within the global malaria portfolio: all the current 
compounds are dual-active TCP-1/TCP-4. However, new 
approaches to in vitro screening directly against hepatic 
schizonts using murine (or ideally human) malaria may 
change this situation [129]. In addition, murine models 
using sporozoites of luminescent parasites allow whole 
animal-imaging of parasites to determine efficacy [138], 
although mouse models that support development of 
human-relevant parasites are, of course, more relevant 
(for example the human liver-chimeric FRG KO huHep 
mouse model supports P. falciparum infection [139]). 
Several new scaffolds have been identified with activi-
ties against P. berghei or P. falciparum liver schizonts, 
including the phosphatidylinosine-4-kinase (PI4K) and 
dihydroorotate dehydrogenase (DHODH) inhibitors, 
and these are also prophylactic in in  vitro assays of P. 
cynomolgi liver schizonts [126, 140]. Guidelines on the 
cellular efficacy are still empirical, and largely based on 
the experience with erythrocytic schizonticides, with a 
threshold activity for candidates of EC50  <  10-100  nM, 
and predicted human PK allowing the minimum prophy-
lactic concentration (assessed in  vivo) to be maintained 
for a week from a single oral dose. Again, empirically, 
this translates into fully protective doses in murine mod-
els with oral administration at <10  mg/kg. Activity can 
be confirmed in CHMI sporozoite challenge studies 
[60–62], and this will help put more objective criteria on 
TCP-4 over the coming years.
One important, emerging consideration is that TCP-4 
can be expanded to include molecules intended for intra-
muscular or subcutaneous administration. Experience 
with vaccination helps define the profile of injection 
volumes below 0.5 ml, preferably subcutaneous, using a 
25 or higher gauge needle, with activity lasting at least 
3 months. Compounds used should have a relatively low 
susceptibility to resistance generation; breakthrough 
strains following intramuscular injections of cyclogua-
nil pamoate in children were all resistant [141, 142], 
presumably due to pre-existing dihydrofolate reductase 
(DHFR)-resistant parasites in the field. The particle size 
and viscosity of the vehicle will be important; penicillin-
G benzathine as a long-acting antimicrobial is precluded 
from routine pediatric use because of the required nee-
dle size [143]. Potency is important too; in psychiatric 
disease, drugs suitable for injection have oral adult doses 
in the 10-mg/day range, and this serves as a useful guide 
to early candidate identification for the long-acting for-
mulation of an anti-malarial. Certain properties, such as 
poor aqueous solubility may now provide an advantage in 
maintaining long-lasting reservoirs, if they can be linked 
to high solubility in lipid vehicles and slow, controlled 
release from the depot. The safety challenges remain 
enormous: long-term safety (6-month exposure), and 
a cautious approach to human volunteer studies would 
be needed, especially for new molecules that have never 
been tested in humans previously. Such studies will nec-
essarily be lengthy.
TCP-5: transmission blocking
One of the key points where the parasite lifecycle can 
be broken is to prevent transmission from the infected 
human host to the mosquito vector. ACT does not block 
transmission, so the current WHO recommendation [72] 
is to use a single, low dose of 0.25 mg/kg primaquine to 
reduce transmissibility of treated P. falciparum infections 
in low-transmission areas. Higher doses are more effec-
tive but their use is limited by concerns over safety in sub-
jects with reduced G6PD activity. Results from a recent 
study resulted in a proposal to dose primaquine by age 
group [144]. The clinical activity of low-dose primaquine 
sets the bar for the next generation of compounds. Pri-
maquine must be metabolically activated, and so cannot 
be used in in vitro models as a control. Mouse-to-mouse 
transmission models exist [145], but use murine para-
sites, and have not been sufficiently cross-validated with 
clinical data to allow their use in decision making. Cur-
rently, direct comparison of transmission-blocking activ-
ity can only be made from data in human subjects.
Transmission can be prevented if mature stage V game-
tocytes are killed or rendered non-functional, and if the 
development of new gametocytes can be stopped. Over 
the last 4  years, the ability to generate enough gameto-
cytes to allow primary screening of large compound 
collections has been realized [108, 146–148]. Full char-
acterization of compounds across a range of in  vitro 
activities, such as exflagellation (male gamete forma-
tion), female gamete formation or oocyst inhibition 
provides additional insight. Compounds may also have 
effects on Plasmodium stages inside the insect vector, 
and these effects are currently captured under TCP-5. 
In the event that new compound series are found with 
well-defined activities on stages in the insect (clearly dis-
tinct from the endectocide activity in TCP-6 below), this 
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will be revisited. Confirmation of the effect on transmis-
sion reduction is measured with the standard membrane 
feeding assay (SMFA) that measures both the number of 
oocysts per midgut (intensity of infection) and the num-
ber of mosquitoes infected (prevalence of infection). 
Considerable improvements in this assay have been made 
in the last 4 years [149, 150], and its outcome is now part 
of the standard decision-making process. Accurate effi-
cacy prediction of the SMFA results from the gametocyte 
counts is currently not possible, so the recommended 
strategy is to use the gametocyte data as a filter to select 
compounds that impact transmission, but to make deci-
sions based on SMFA data at the lead-to-candidate stage.
The link between the SMFA data and human transmis-
sion-blocking capability has also yet to be elucidated. The 
observation that in the CHMI model, piperaquine treat-
ment causes a consistent decrease in the female gameto-
cyte marker Pfs25, opens up new possibilities to use this 
to rank clinical candidates for their transmission-block-
ing activity [122]. However, a male stage V gametocyte 
marker is similarly required to properly interpret the 
potential of a compound, particularly since, from in vitro 
data, the majority of mechanisms appear to predomi-
nantly impact only male gametocytes [151]. Understand-
ing the duration of exposure that is required will also be a 
critical factor here; artemether incapacitates gametocytes 
in culture [152], and an analysis of 62 studies concluded 
that artemether–lumefantrine has consistent gametocy-
tocidal effects [153–155].
The clinical development pathway for an exclusively 
transmission-blocking compound is still not well defined. 
Until now, all transmission-blocking candidates have also 
had activity against the asexual blood stages. Discussions 
about the approval pathway for a transmission-blocking 
vaccine [156] suggest a route forwards, which could be 
based on finding activity in CHMIs followed by a dem-
onstration of the reduction of infections at a commu-
nity level over a prolonged period [157], then seeking 
approval through a standard treatment regulatory path 
for adding such an agent to a double combination. A 
strategy focused on targeting vector-stage parasites only 
would rely on mosquitoes biting while drug levels are still 
in the efficacious range. Since, in the absence of a game-
tocytocidal agent, infective stage V gametocytes can cir-
culate for beyond 20 days, such a strategy is only feasible 
if drug concentrations are extremely protracted; this is a 
considerable challenge that conceivably could be over-
come with intramuscular dosing or orally, with the use 
of particularly stable compounds. The latter is discussed 
in the next section in the context of medicines that kill 
mosquitoes following the drug’s uptake in a bloodmeal: 
endectocides.
Direct effect on the insect vector (potential TCP-6)
Studies with the endectocide ivermectin, used to treat 
onchocerciasis (river blindness), lymphatic filariasis and 
strongyloidiasis, have demonstrated a significant effect 
on these parasites as well as the morbidity and mortality 
of insects feeding on subjects with plasma concentrations 
of the drug. Merely shortening the insect vector’s lifes-
pan is predicted to have a significant impact on malaria 
transmission, since oocyte maturation is a slow, highly 
temperature-dependent process that requires almost all 
of the adult mosquito’s remaining lifetime. Widespread 
treatment of populations with such endectocides has 
been proposed as a potential approach in the eradication 
of malaria [158]. This TCP has been the discussion of a 
2016 expert review by the WHO, and several topics are 
worth underlining. The optimal ivermectin regimen [159] 
requires a higher dose or longer duration of therapy than 
the single 200 μg/kg used in onchocerciasis, and for this, 
additional clinical safety data would be needed. Modelling 
is also needed to predict the human population coverage 
required for a significant effect, since the current label pre-
cludes women of child-bearing potential, in the absence of 
data on first-trimester pregnancy use. Pricing is unlikely to 
be an issue; ivermectin is relatively cheap, at $750/kg, and 
the doses are low. Ultimately, the challenge is that the half-
life of ivermectin in humans is 18–35  h, suggesting that 
it is likely to have a short duration of action. Long-acting 
formulations have been proposed for such a TCP, and also 
newer generations of veterinary-approved isoxazolines 
have 3 months of coverage, and offer an alternative route 
forward.
Portfolio considerations for choosing combination 
components
One of the most difficult issues with managing the port-
folio is navigating the maze between the early studies (up 
to clinical proof of concept in volunteers or patients) and 
the later stages, where compounds are used exclusively in 
combination. Selection of which molecules to combine, 
and how, depends principally on four factors: efficacy, 
safety, propensity to generate resistance, and ability to be 
co-formulated:
Efficacy
For efficacy, simple isobolograms are often used to iden-
tify highly significant synergies in the partners’ IC50s, 
and a lack of significant antagonism. However, these 
rely on parasite growth inhibition assays, which give no 
information on ‘killing’; the most relevant in vitro stud-
ies involve examining the effect of combinations (at dif-
ferent concentrations of each drug) in the PRR assay, 
since this informs with respect to synergistic, additive or 
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antagonistic effects on the rate of parasite killing. This is 
the closest in vitro endpoint to mirror what is then meas-
ured in mice and humans: in vivo parasite clearance. The 
next stage will be to better understand whether any inter-
action is seen between two compounds when they are 
dosed as a combination in the in vivo NOD SCID mouse 
model, where the speed of killing is assessed, but also 
the initial delay in onset of activity. These results could 
then be used to guide testing of combinations in the 
CHMI model in volunteers. Critically, both the in  vitro 
and in vivo mouse and human data can be modelled to 
investigate alterations in the potency (MIC and MPC), 
the PRR and time to recrudesce. Combined with mod-
elling, this should provide a clear rationale for partner 
and dose range selection in the phase IIb studies. In the 
event that single doses of two molecules do not provide 
sufficient coverage to achieve cures in at least 95% of 
the patients, then the next approach would be to extend 
to three or more molecules. This is not new for malaria 
either: artesunate–sulfadoxine–pyrimethamine is already 
widely used in India. However, the triple combination 
chlorproguanil–dapsone–artesunate failed for safety 
issues related to dapsone; moreover, the combination of 
the three active drugs did not achieve a 95% cure rate 
[160, 161]. Note that this triplet included molecules that 
each had a short half-life. Adding more drugs may gener-
ate more problems than it solves in some situations.
Safety
For safety, there are two aspects. First, to understand 
the individual compound liabilities, and second to use 
clinical observation and metabolic modelling to establish 
whether two compounds have a drug interaction such 
that one compound inappropriately modulates the PK 
curve of the other, perhaps causing an increased safety 
risk. Such modelling typically involves physiologically 
based PK models, and MMV is working with Certara 
using the Simcyp simulator to better manage this risk 
[162].
Resistance
There should be no evidence of clinically relevant resist-
ance to either molecule. For new molecules where the 
resistance marker is known, an interrogation of the 
genomes of sequenced parasites is prudent in confirm-
ing the absence of deleterious pre-existing mutations. 
Furthermore, cross-resistance studies can be conducted 
in which each drug is tested to confirm that it can kill all 
resistant clones when combined with the partner drug. 
A combination in  vitro selection study should similarly 
confirm a reduction in the risk of resistance generation. 
The ideal situation is that the compounds are individu-
ally resistance-proof (at a level of detection of 1 in 109) 
coming from chemical series where it is difficult to raise 
resistance in  vitro. The fitness costs for resistance may 
also play a role; it appears that Plasmodium appears una-
ble to maintain resistance against certain pairs of drugs, 
such as mefloquine and piperaquine, at the same time 
[163]. Finding other such mutually exclusive pairings in 
the portfolio will be important over the next period. An 
emerging area of parasitological understanding is the 
confirmation and relevance of asexual blood-stage dor-
mancy or quiescence, and whether certain compounds 
promote dormancy or, in contrast, can kill or re-activate 
any putative dormant forms [164–166]. Such resistance 
mechanisms are extremely complicated and more basic 
science is required to understand the clinical significance 
of in  vitro studies in this area. Naturally, as the state of 
the art develops, the drug combination criteria develop 
too. If clinical dormancy is confirmed and robust assays 
become available, clearance of such parasites, within a 
combination, will be critical. Triple combinations have 
been mentioned above in relation to efficacy but could 
equally be considered from a resistance perspective to 
preserve the longevity of a combination. If pre-existing 
mutations resistant to any one drug in a double combina-
tion exist then it could be argued that the ‘double’ com-
bination is actually ‘monotherapy’. Triple combinations 
would mitigate this risk.
Formulation
Finally, the formulation compatibility question becomes 
important when assessing a single-dose cure. The total 
amount of drug used is likely to be high, considering the 
current molecules in the portfolio, where very few have 
a predicted or confirmed therapeutic dose of <100  mg. 
The requirement for complex formulations can there-
fore increase the total amount of material administered, 
and above certain levels, this is unacceptable. The use of 
complex formulations will have an impact on costs. The 
current formulations of ACT are priced between $1.00 
and $3.00, when an adult course of therapy is purchased 
in a public health setting. While current therapies retain 
efficacy in Africa it is hard to see that new drugs with 
higher prices would have a significant impact on the mar-
ket. If current ACT fails in Africa the value of new drugs 
increases dramatically, and so the minimal acceptable 
cost profiles will change.
How strong is the current portfolio?
An earlier analysis [4] showed that the attrition rate in 
malaria medicine development closely follows the Cen-
tre for Medicines Research (CMR) international bench-
marks for anti-infective medicines in general. This means 
that malaria drug discovery has an attrition rate that is 
no better and no worse than that in the pharmaceutical 
Page 22 of 29Burrows et al. Malar J  (2017) 16:26 
industry for anti-infectives overall, and significantly 
better than for other therapeutic areas, such as neurol-
ogy and oncology. One difficulty with such an analysis 
is that new chemotypes have an inherently higher risk 
than additional members of established chemical classes, 
other than the risks of failure due to resistance (which 
are higher for drugs that have been used for many years). 
For this review’s new analysis (Table 8), new chemotypes 
are separated from life-cycle management projects. The 
overall success rates have not changed significantly in the 
last 3 years, either for MMV or for the CMR benchmark, 
which is reassuring. The data shows that a new molecule 
in formal preclinical evaluation has an 8% chance of 
becoming part of a product.
The naïve interpretation of this is that no more than 13 
candidate compounds would be needed for a reasonable 
chance of launching one new medicine, and 25 for a com-
bination with two NCEs (new chemical entities). How-
ever, if one aims for a 90% overall chance of success (P), 
the number of candidates n, each with a success probabil-
ity s (8%) is described by the negative binomial distribu-
tion in Eq. 1. 
This equation represents the relationship between P, or 
the overall probability of discovering two or more suc-
cessful medicines, the number n of candidate molecules 
pursued, and success probability s for each candidate.
In this expression the left term denotes the overall fail-
ure to discover at least two successful medicines from a 
set of n candidate molecules. The terms on the right add 
the probabilities of finding zero, or exactly one successful 
(1)(1− P) = (1− s)n +
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medicine when following up n candidate molecules. The 
numerical solutions for this equation show that at least 
48 molecules are to be evaluated for this probability 
to exceed 90%. The MMV discovery portfolio was built 
and funded to deliver two new preclinical candidates per 
year, and allowing for a third molecule coming from else-
where, then this would still require some 16 years’ invest-
ment per combination, except if there is a considerable 
increase in success rates going forwards (and a justifica-
tion for this), or significantly increased investment. The 
hope on the horizon is that many of the new molecules 
are first-in-class, and so should they fail in clinical devel-
opment there will be scope for well-defined back-up pro-
jects, and these are normally much more cost-effective 
programmes. The definition of new molecular targets 
also opens up new possibilities for engaging the wider 
research community, allowing access to resources such as 
the EU’s European Lead Factory, which considers molec-
ular targets but not phenotypic approaches.
The factors underlying these metrics merit closer atten-
tion. The increased stringency of review of projects at 
the lead and preclinical candidate stages means that 
the quality of compounds is theoretically improving, so 
future success rates may be underestimated [112]. Of the 
16 molecules entering preclinical development from the 
MMV portfolio since 2009, only four have been aban-
doned, with six moving successfully to phase I, and a fur-
ther seven working their way through safety studies, with 
four new phase I starts expected in 2017. As Fig. 3 with 
plots for Eq. 1 shows, doubling the success rate for indi-
vidual candidate molecules (from 8 to 16%) more than 
halves the number that need to be evaluated. One area 
for possible improvement is the success rate in phase III, 
Table 8 Success rates (%) in development 2009–2014 for MMV compared to benchmark data, by phase
a LCM: Life cycle management; these are the medicines that were brought into the MMV portfolio when it was already clear that they are well tolerated and effective, 
but the task was to generate new formulations or co-formulations
b Pharmaceutical Benchmarking Forum; CMR data 2013
c PBF data 2010
d Stage success rate of 60% for combining two medicines has been added into reflect the potential for unfavourable drug–drug interactions that prevents further 
development of a combination. However, as discussed in the text, this may be an underestimate, since it does not include additional risk because of the change in 
endpoints between parasite reduction in phase IIa (APCR on day 14 or 28) and ACPR day 28 in phase IIb. No additional allowance has been made for the risk that a 
medicine may fail because it is not possible to produce a pediatric presentation
MMV CMRa PBFb
Excluding LCMc Including LCM
Per phase Cumu-lative Per phase Cumu-lative Per phase Cumu-lative Per phase Cumu-lative
Preclinical 50 8 50 14 60 5 40 3
Phase I 70 16 70 27 56 9 54 7
Phase IIa 75 23 78 39 36 16 34 13
Phase IIb 60d 30 75 50 60d 45 60d 38
Phase III 50 50 67 67 84 75 70 64
Registration 100 100 100 100 89 89 91 91
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which is currently only 50%. The frequent phase III fail-
ures in other therapeutic areas have been linked to pre-
mature decisions to proceed to phase III, due to external, 
non-scientific pressures, without appropriately strong 
phase II data [167]. On the other hand it is difficult to 
estimate the additional risk factor for putting together 
new compounds in phase IIb, cited as 60%. However, this 
is still only an estimate.
It also remains a question as to whether this level of 
delivery of preclinical candidates can be maintained. The 
initial momentum was provided by phenotypic screening 
of diverse compound collections. New chemical diversity 
has been screened in the last 4  years, including micro-
bial metabolites from Japan, and molecules with novel 
chemistries such as boron [168, 169] and increased sp3 
types [170]. These sources are rapidly being mined out 
and it is only through access to novel chemical diver-
sity via new pharmaceutical compound libraries that 
new relevant compounds can be screened. Examples for 
these creative sources include compounds that popu-
late Lilly’s Open Innovation Drug Discovery platform 
[171] or the Community for Open Antimicrobial Drug 
Discovery (COADD) [172] and the direct selection of 
compounds for screening that come from emerging in 
silico models [173]. Other strategies include investigat-
ing compounds in the 1–10 μM range of potency (which 
up until now have been considered too weak) and retest-
ing those compounds already screened in new assays, 
not least phenotypic assays, against non-asexual blood 
stages of the parasite. An exciting development is the 
emergence of new, validated molecular targets [6], which 
have the advantage that they are already known to be 
druggable, often with in  vivo, and sometimes clinical 
validation. Some of these targets are enzymes: DHODH, 
PI-4 kinase and the elongation factor EF2, where the 
three-dimensional structures may be accessible, driving 
target-based discovery of new scaffolds. In the event of 
increased attrition in the early clinical pipeline, there will 
be a potential for fast-follower, next-generation projects 
to fix the issues; these must be ‘differentiated back-ups’, 
rather than simple ‘me-too’ compounds. The next-gen-
eration compound will be specifically designed to over-
come the problems encountered by the first compounds. 
Testing multiple, diverse scaffolds against the same path-
way is the only way to ensure ultimate delivery.
Discussion
The malaria eradication agenda has set new challenges for 
drug discovery. The central hypothesis is that controlling 
malaria will always be a costly activity, requiring a con-
tinual pipeline of new medicines to overcome acquired 
drug resistance as and when it emerges. Most elimination 
strategies proposed require an initial reduction in trans-
mission by vector control, followed by multiple rounds 
of medicines used in MST or MDA settings, and finally 
methods to stop re-introduction, or to prevent epidem-
ics. New medicines will need exquisite levels of clinical 
safety and tolerability. On top of this, the new medicines 
need to break the transmission cycle. Although there has 
been considerable success over the last 4  years in find-
ing molecules with transmission-blocking potential, it is 
only now that early discovery is able to start with that end 
in mind, and screen primary diversity for this potential 
rather than retro-fitting it onto blood-stage actives.
Against these exceptionally high hurdles, there is a 
much stronger portfolio of new preclinical candidates. 
Most of the newer compounds were selected because of 
a significant PRR, at least in vitro, and were optimized to 
maximize their plasma residence time. The new genera-
tion of compounds kills as fast as mefloquine, or faster, 
and can maintain activity for up to 8  days, and the risk 
of unmatched pharmacological duration of cover is 
somewhat diminished [115]. This review has simplified 
the classification, describing all compounds with activ-
ity against blood stages as TCP-1, provided that they 
are predicted to be capable of a reduction in parasitemia 
of at least 106-fold in humans. But ideally a new mol-
ecule should be able to kill all the parasites in all patient 
groups, with a 1012-fold reduction of parasitemia at expo-
sures equivalent to those in the lowest 5% of the popula-
tion. In reality one can only measure 106–107-fold drops 
in parasitemia by PCR, and so any number greater than 
this is an extrapolation.
Making sure that compounds progress quickly through 
the pipeline is important. Preclinical development can 
be achieved at ‘industrial speeds’, as illustrated by the 
14 months needed for artefenomel. However the cost in 



























Number of candidate compounds n evaluated




P for s = 8 %
P for s = 16 %
n=23
n=48
Fig. 3 Probability (P) of delivering two or more new medicines after 
evaluating n candidate molecules, each with a probability of success 
(s) of 8 or 16%. The red line indicates an overall delivery success of 
90%, with minimal n-values indicated for each curve
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III. Activities can be carried out in parallel, however the 
cost/risk impact needs to be carefully considered, and 
streamlined decision-making processes and full up-front 
funding are required. The availability of human challenge 
models has accelerated development for two reasons. 
First, it gives increased confidence in the molecule and 
this is important in allowing timely decisions to invest in 
the later clinical phases. Second, the selection of doses 
for phase II can be informed early in phase I, allowing 
early submission of clinical protocols before phase I is 
complete. This can significantly accelerate initiation of 
phase II studies, since the approval of these protocols 
in disease-endemic countries can take between 4 and 
18  months. Early confidence in molecules is a critical 
success factor.
For anti-relapse molecules, there has been progress 
over the last 4 years, but no new candidates yet. Tafeno-
quine has demonstrated anti-relapse efficacy at a single 
dose of 300  mg, and is now on the cusp of regulatory 
submission. However, there are no new molecules with 
TCP-3 activity following it in the pipeline. The major 
development is that there are now at last cellular assays 
capable of testing hundreds of molecules for this TCP, 
and this may spur a new era in anti-relapse drug discov-
ery over the next few years, although there is no certainty.
The pipeline has been significantly enriched in new 
molecules with activity against hepatic schizonts, which 
could be used in chemoprotection and perhaps chemo-
prevention regimens. Around half of the chemotypes 
identified by their activity against asexual stages have 
activity against hepatic schizonts. These include KAF156 
[9, 174], DSM265 [11], MMV048 and DDD498 [6].
Finally, there are a large number of new molecules 
which display activity in transmission-blocking assays 
in  vitro, at concentrations that might be achieved clini-
cally. Examples already in clinical development include 
OZ439, KAE609, KAF156, SJ733, and DDD498. The abil-
ity to test for activity against gametocyte survival over 
time, and against viable transmission to insects in CHMIs 
will help a better understanding of the combination of 
cellular activities and clinical PK required to achieve a 
clinical effect. Ideally one of the two (or three) drugs in 
a new combination would have transmission-blocking 
activity. An alternative approach would be to add a low 
dose of primaquine to a combination, provided that pri-
maquine does not have a negative drug–drug interaction 
with one of the blood schizonticides.
Conclusions
The shift from control to elimination of malaria set 
ambitious goals for treatment and chemoprevention of 
malaria, at a time when only a handful of new molecules 
entered preclinical development over the preceding 
decade. The last 4 years has seen the continued arrival of 
new molecules, a deepening understanding of the mol-
ecules in the pipeline, a more profound understanding of 
how to combine these molecules, and, of course, lessons 
learned from attrition in the pipeline. The use of early 
clinical studies allowing for longer term follow-up (to 
28  days) or controlled human malaria infection studies 
allows characterization of the key performance param-
eters such as the PRR and the MIC and MPC for each 
molecule, and in combination.
Over the next 4-year period an understanding of how 
to translate these parameters into the key output for new 
treatments (ACPR and cure) will deepen as a result of 
having more clinical phase IIb data. These should provide 
a more quantitative framework for assessing the impact 
of patient genetic background and immune status. Resist-
ance continues to be an issue; all of the new medicines 
must be as resistance proof as possible, and discussion 
about the medicines needed in severe malaria should 
artemisinin fail needs to be revived. The largest gap in the 
portfolio is the absence of molecules for the anti-relapse 
profiles, although there is some optimism now that cel-
lular assays start to become available. For transmis-
sion blocking, there are now many molecules with good 
in vitro activity, and over the next few years these will be 
tested in CHMI models to see how their transmission 
blocking activity compares to low-dose primaquine. New 
endectocide approaches have been proposed, but are still 
at an early stage, and their ultimate hurdle will clearly 
be the adoption by malaria-affected countries. There 
are also several molecules with hepatic schizont activity, 
with potential for use in chemoprotection, and sporozo-
ite challenge models will provide data to help refine pre-
dictions on how to link cellular activity and human PK to 
better predict clinical activity. Such a medicine is vital in 
the final phases of eradication where maintaining zero 
transmission during potential epidemics is critical. The 
current chemoprotection options are extremely limited: 
atovaquone-proguanil, because of its daily administra-
tion, and mefloquine because of its safety profile.
The recently published Global Technical Strategy 
for Malaria sets out an aggressive agenda for reducing 
malaria incidents and deaths by 90% over the period 
2016–2030 [3]. This plan is aggressive in that such a 
fall is more significant than that seen over the previ-
ous 15  years, and is set against a continuing threat that 
multidrug-resistant malaria may emerge in Africa at any 
point during that period. However, even allowing for suc-
cess, there would still be an unacceptable 40,000 deaths 
and 20 million cases of malaria per year, and a need for 
new medicines to be launched in the decade after this 
timeframe. To continue the current rate of productivity 
will require new strategies for hunting out and designing 
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clinical candidates, and continued increases in efficiency 
to not only test compounds, but pick the winners early. 
In short, this will require a continual focus on finding the 
transformative new medicines described by these target 
product profiles.
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intermittent preventive treatment in infants; IPTp: intermittent preventive 
treatment in pregnancy; malERA: malaria eradication agenda; MDA: mass drug 
administration; MIC: minimum inhibitory concentration; MMV: medicines for 
malaria venture; MPC: minimum parasiticidal concentration; MRI: magnetic 
resonance imaging; MST: mass screen-and-treat; NOAEL: no observed adverse 
effect level (dose); NOD SCID: non-obese diabetes, severe immunodeficient; 
PI4K: phosphatidylinosine-4-kinase; PCR: polymerase chain reaction; PD: 
pharmacodynamic(s); PK: pharmacokinetic(s); PrEP: pre-exposure prophylaxis; 
PRR: parasite reduction rate; RDT: rapid diagnostic test; RH: relative humidity; 
SDC: single dose cure; SEC: single exposure chemoprotection; SERC: single 
encounter radical cure; SERCaP: single encounter radical cure and post-treat-
ment prophylaxis; SMC: seasonal malaria chemoprevention; SMFA: standard 
membrane feeding assay; SRA: stringent regulatory agency; TB: tuberculosis; 
TCP: target candidate profile; TPP: target product profile; WHO: World Health 
Organization.
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